MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.
Looking for a particular MaaT Pharma employee's phone or email?
The MaaT Pharma annual revenue was $4 million in 2026.
Carole Schwintner is the CTO of MaaT Pharma.
62 people are employed at MaaT Pharma.
MaaT Pharma is based in Lyon, Auvergne-Rhone-Alpes.
The NAICS codes for MaaT Pharma are [511210, 54, 541, 5112, 51, 51121, 511].
The SIC codes for MaaT Pharma are [737, 87, 73, 80].